Rochester, NY – [Insert Date] – Bausch + Lomb, a global leader in eye health, has announced a significant step forward in its ophthalmic drug development pipeline, with two promising therapeutic candidates poised to enter their next crucial clinical phases. One candidate, an innovative eye drop designed to address the multifaceted symptoms of dry eye disease, will advance to pivotal Phase III trials. Concurrently, another investigational therapy, BL1332, targeting ocular surface pain, has demonstrated compelling efficacy in early-stage studies and will proceed to Phase II development. This dual progression underscores Bausch + Lomb’s commitment to addressing unmet needs within the ophthalmology sector.
n
The decision to advance these candidates reflects a strategic evaluation of robust scientific data and a clear vision for their potential impact on patient care. While the dry eye candidate’s journey has encountered a nuanced efficacy profile, the company’s leadership expresses strong confidence in its unique therapeutic approach. The advancement of BL1332, on the other hand, is propelled by overwhelmingly positive results in alleviating ocular surface pain, validating a novel mechanism of action.
n
A Dual-Action Approach to Dry Eye Disease Moves to Phase III
n
Bausch + Lomb’s novel eye drop formulation for dry eye disease represents a significant endeavor to develop a single product capable of addressing both inflammation and tear evaporation, two primary drivers of the condition. This dual-action approach aims to offer a more comprehensive solution than many existing treatments, which often focus on one aspect of the disease. The therapy is set to enter Phase III development following encouraging, albeit complex, results from its Phase II study.
n
The Phase II study, conducted over four weeks with a twice-daily dosing regimen, evaluated the efficacy of the combination therapy. This investigational drug combines lifitegrast, the active ingredient in Bausch + Lomb’s own dry eye medication Xiidra, with perfluorohexyloctane, a key component of Miebo, a Novaliq-licensed therapy. The rationale behind this combination is to leverage the anti-inflammatory properties of lifitegrast with the lipid-replenishing and tear-stabilizing effects of perfluorohexyloctane.
n
Chronology of the Dry Eye Candidate’s Development:
n
- n
- Early Development: The foundational components, lifitegrast and perfluorohexyloctane, were established through prior research and licensing agreements, including the acquisition of Xiidra from Novartis and the licensing of Miebo from Novaliq.
- Phase II Study Design: A four-week, randomized, controlled study was initiated to assess the efficacy and safety of the combination therapy in patients with dry eye disease. The study employed a twice-daily dosing schedule.
- Primary Endpoint Miss: The study’s primary endpoint, a statistically significant reduction in corneal staining compared to lifitegrast alone at the end of the four-week treatment period, was not met. Corneal staining is a common objective measure of ocular surface damage in dry eye.
- Secondary Endpoint Success & Nuanced Data: Despite missing the primary endpoint, the combination therapy demonstrated a numerical trend towards improvement in corneal staining at day 29. Crucially, a pre-specified secondary analysis revealed a statistically significant mean change in corneal staining at day 15. Bausch + Lomb highlighted that the U.S. Food and Drug Administration (FDA) recognizes 15 days as a valid timepoint for assessing efficacy in registrational studies for dry eye treatments.
- Safety Profile: The combination therapy exhibited a safety profile comparable to its individual components, with no new or unexpected safety signals identified during the study. This is a critical factor for advancing any new therapeutic.
- Decision to Advance to Phase III: Based on the totality of the data, particularly the positive day 15 results and the potential for a dual-action mechanism, Bausch + Lomb has decided to advance the therapy to Phase III development.
n
n
n
n
n
n
n
Supporting Data and Rationale for Phase III Progression:
n
The decision to move forward to Phase III, despite the primary endpoint miss, is rooted in several key observations from the Phase II trial. While the four-week study did not show statistical superiority over lifitegrast alone in reducing corneal staining at the conclusion of the trial, the earlier positive signal at day 15 is a significant factor. This suggests that the combination therapy may exert its beneficial effects earlier in the treatment course, a finding that aligns with the FDA’s acceptance of earlier timepoints for registrational studies.
n
Furthermore, the observed numerical trend towards benefit at day 29 indicates that the treatment effect may continue to evolve, even if it did not reach statistical significance within the four-week timeframe. The combination therapy’s ability to achieve these results with potentially less drug than administering lifitegrast and perfluorohexyloctane separately is also a compelling aspect. This could translate to improved patient tolerability and potentially lower manufacturing costs.
n
The absence of new safety signals is paramount. For any chronic condition like dry eye, a favorable safety profile is as critical as efficacy. The fact that the combination therapy did not introduce any new adverse events provides a solid foundation for further investigation in a larger patient population.
n
Official Response and Strategic Vision:
n
Yehia Hashad, Chief Medical Officer and Executive Vice President of R&D at Bausch + Lomb, articulated the company’s rationale for advancing the dry eye candidate. He emphasized the "pre-specified result achieved with less drug than the individual therapies, and the ability to increase the dose based on an acceptable safety profile." Hashad expressed the company’s "high conviction" in the drug’s potential, suggesting that the nuanced data, when viewed holistically, supports continued development.
n
The strategic vision behind this dual-action eye drop is to fill a significant gap in the current dry eye treatment landscape. While numerous therapies are available, few effectively target both the inflammatory pathways and the evaporative component of dry eye simultaneously. By combining the anti-inflammatory action of lifitegrast with the lipid layer stabilizing and tear evaporation reduction properties of perfluorohexyloctane, Bausch + Lomb aims to offer a more comprehensive and potentially superior therapeutic option for the millions suffering from this debilitating condition.
n
BL1332: A Novel Approach to Ocular Surface Pain Poised for Phase II
n
In parallel, Bausch + Lomb’s investigational therapy BL1332 is set to embark on Phase II development, buoyed by highly encouraging results from its Phase Ib trial. This candidate is being developed to address ocular surface pain, a significant and often undertreated symptom that can severely impact a patient’s quality of life. The drug’s mechanism of action targets the TRPV1 receptor, a key player in the sensation of pain and heat on the ocular surface.
n
The Phase Ib trial involved healthy volunteers and employed a capsaicin challenge to induce a controlled, temporary sensation of ocular pain, mimicking the "spicy" sensation experienced from chili peppers. This methodology is a well-established way to evaluate the efficacy of pain-relieving compounds in a safe and reproducible manner.
n
Chronology of BL1332’s Development:
n
- n
- Mechanism of Action Identification: Research identified the TRPV1 antagonist mechanism as a promising target for alleviating ocular surface pain.
- Phase Ib Trial Conducted: A Phase Ib study was initiated in healthy volunteers to assess the safety and preliminary efficacy of BL1332.
- Capsaicin Challenge Introduced: Participants were exposed to a capsaicin challenge to induce controlled ocular pain.
- Positive Efficacy Data Emerged: BL1332 demonstrated a significant reduction in pain intensity compared to a placebo (vehicle).
- Advancement to Phase II: Based on the compelling efficacy and safety profile observed, Bausch + Lomb has decided to advance BL1332 to Phase II development.
n
n
n
Supporting Data and Validation of Mechanism:
The results from the Phase Ib trial for BL1332 are remarkably positive and provide strong validation for the TRPV1 antagonist approach in treating ocular pain. Following the capsaicin challenge, eyes treated with BL1332 exhibited a substantial reduction in pain intensity. Specifically:
- Pain Intensity Reduction: Within five seconds of the capsaicin challenge, participants treated with BL1332 experienced an average drop of 5.5 points in pain intensity compared to those who received the vehicle. This represents a clinically meaningful reduction in perceived pain.
- Complete Pain Resolution: A significant proportion of participants treated with BL1332 achieved complete resolution of pain. 68.2% of eyes treated with the drug experienced no pain post-challenge, a stark contrast to the 0% reported in the vehicle arm.
- Absence of Severe Pain: Crucially, none of the participants who received BL1332 reported experiencing severe pain following the capsaicin challenge. In contrast, 36.4% of individuals in the vehicle group reported severe pain. This highlights the drug’s ability to not only reduce pain but also prevent it from escalating to severe levels.
- Safety and Tolerability: While specific safety data details from the Phase Ib trial were not elaborated upon in the provided text, the progression to Phase II implies an acceptable safety and tolerability profile in healthy volunteers.
These findings are highly significant as they directly demonstrate BL1332’s ability to effectively block the pathways that transmit pain signals from the ocular surface. The drug’s efficacy in a capsaicin challenge model strongly suggests its potential to alleviate pain associated with various ocular conditions.
Implications and Future Development:
The successful outcome of the Phase Ib trial provides a robust foundation for Bausch + Lomb to investigate BL1332 in patients suffering from relevant eye pain conditions. The company is already exploring the drug’s potential in an ongoing Phase II study specifically designed for patients experiencing pain following eye surgery. Post-operative ocular pain is a common and often distressing complication, and an effective treatment could significantly improve patient recovery and satisfaction.
The TRPV1 antagonist mechanism is a novel and promising avenue for addressing ocular pain, which can be notoriously difficult to manage with current therapies. By targeting this specific receptor, BL1332 offers a targeted and potentially more effective approach to pain relief, moving beyond general analgesics that may have systemic side effects.
Broader Implications for Ophthalmic Care
The concurrent progression of these two distinct ophthalmic candidates underscores Bausch + Lomb’s strategic commitment to innovation across multiple therapeutic areas within ophthalmology. The company’s efforts in dry eye disease aim to address a condition affecting millions globally, with a focus on a novel dual-action mechanism. Simultaneously, the development of BL1332 signifies a dedication to alleviating ocular surface pain, a critical unmet need that can profoundly impact patient well-being.
The success of these programs could lead to the introduction of new, highly effective treatments that improve the quality of life for patients suffering from these common and often challenging eye conditions. The industry will be closely watching the progress of both the dry eye candidate through its Phase III trials and BL1332 as it continues its Phase II investigation, hopeful for breakthroughs that can redefine standards of care in ophthalmology.
